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Abstract  
AIM: We aimed study impact of hepatocytic viral load, steatosis, and iron load on fibrosis in chronic 
hepatitis C and role of VEGF and VEGFR overexpression in cirrhotic cases in evolving HCC. 
MATERIAL AND METHODS: Total of 120 cases were included from TBRI and Beaujon Hospital as 
chronic hepatitis C (CHC), post-hepatitis C cirrhosis, and HCC. Cases of CHC were stained for 
Sirius red, Prussian blue and immunohistochemically (IHC) for HCV-NS3/NS4. HCC were stained 
IHC for VEGF and by FISH.  
RESULTS: Stage of fibrosis was significantly correlated with inflammation in CHC (P < 0.01). 
Noticed iron load did not correlate with fibrosis. Steatosis was associated with higher inflammation 
and fibrosis. The cellular viral load did not correlate with inflammation, steatosis or fibrosis. VEGF 
by IHC was significantly higher in cases of HCC when compared to cirrhotic group (P < 0.001). 
Amplification of VEGFR2 was confirmed in 40% of cases of HCC. Scoring of VEGF by IHC was the 
good indicator  of VEGFR2 amplification by FISH (P < 0.005).  
CONCLUSION: Grade of inflammation is the factor affecting fibrosis in CHC. The degree of liver 
damage is not related to cellular viral load or iron load. Steatosis is associated with higher 
inflammation and fibrosis. VEGF by IHC is correlated with overexpression of VEGFR2 by FISH. 
 
 
 
 
 
Introduction 
 
Hepatitis C virus (HCV) is a global epidemic 
affecting approximately 3% of the world's population. 
Egypt has the highest prevalence of hepatitis C virus 
(HCV) in the world, estimated nationally at 14.7%. Our 
study's objective was to delineate the evidence on the 
epidemiology of HCV infection among the different 
population groups in Egypt and to draw analytical 
inferences about the nature of HCV transmission in 
this country [1]. In the 15–59 year age groups, the 
prevalence of HCV antibody was found to be 10.0% 
(95% CI = 9.5 –10.5) and that of HCV RNA to be 7.0% 
(95% CI = 6.6–7.4). In children, 1–14 years old, the 
prevalence of HCV antibody and HCV RNA were 
0.4% (95% CI = 0.3–0.5) and 0.2% (95% CI = 0.1–
0.3) respectively. Approximately, 3.7 million persons 
have chronic HCV infection in the age group 15–59 in 
2015. An estimated 29% reduction in HCV RNA 
prevalence has been seen since 2008, which is 
largely attributable to the ageing of the group infected 
40–50 years ago during the mass schistosomiasis 
treatment campaigns. Prevention efforts may have 
also contributed to this decline, with an estimated 75% 
(95% CI = 6–45) decrease in HCV incidence in the 0–
19 year age groups over the past 20 years [2]. 
Steatosis is a complication of HCV infection 
and the mechanisms of its development are complex, 
involving viral and host factors. Steatosis that is 
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prevalently viral is associated with HCV genotype 3, 
and steatosis that is prevalently metabolic is 
associated with non-3 genotypes. Viral steatosis is 
correlated with the level of HCV replication, whereas 
metabolic steatosis is related to insulin resistance. 
The two types of steatosis have a different impact on 
HCV disease and may have an additive effect [3]. 
It has been generally accepted that either 
steatosis by itself aggravates fibrosis or the factors 
that are causing steatosis may be aggravating 
fibrosis. Overall, steatosis, whether metabolic or HCV 
induced, worsens the sequence of events leading to 
advanced fibrosis in patients with HCV and needs to 
be addressed when managing patients with HCV [4]. 
Syed and Sadiq [5] have found a positive 
association between HCV-NS3 immunopositivity and 
the histological parameters of grading and staging, 
suggesting that greater amounts of virus are present 
in more advanced chronic liver disease. 
Iron overload in the liver induces oxidative 
stress leading to cell membrane damage, DNA 
instability and mutagenesis [6]. Due to these effects, 
iron can be considered a proinflammatory, 
profibrogenic factor and a potential carcinogen. Since 
the implementation of serological diagnostic tests for 
HCV identification, elevated serum iron-overload 
indices or appearance of iron deposits in liver cells 
have been observed in 10-40% of patients with 
chronic hepatitis C and 50% of patients suffering from 
both chronic hepatitis C (CHC) and HCC [7]. 
There is evidence that iron overload leads to 
an increased risk of HCC, failure of antiviral treatment 
and significantly worsens clinical outcomes in patients 
suffering from chronic HCV infection [8]. Clinically, 
HCC tends to be hypervascular and, for that reason, 
transarterial chemoembolization has proven to be 
effective in managing many patients with localised 
disease. More recently, angiogenesis has been 
targeted effectively with pharmacologic strategies, 
including monoclonal antibodies against vascular 
endothelial growth factor (VEGF) and VEGF 
receptors, as well as small-molecule kinase inhibitors 
of the VEGF receptor [9]. 
 
The aim of this paper was to study the impact 
of the hepatocytic viral load, hepatocytic steatosis, 
and hepatic iron and copper load on fibrosis in a 
sample of chronic hepatitis C and to study the role of 
VEGF and VEGFR overexpression in a sample of 
cirrhotic cases in evolving HCC. 
 
 
Material and Methods 
 
The material of this study is retrieved from the 
archives of Pathology Departments of Theodor Bilharz 
Research Institute – Giza, Egypt and Beaujon 
Hospital – Clichy, France during the years 2013 and 
2014. For each case, personal, medical and clinical 
data were obtained from the records of Pathology 
Departments of both centers and cases that match the 
following criteria were included: Positive HCV mRNA 
by PCR, no history of treatment or previous 
transplantation, no evidence of concomitant hepatitis 
B virus (HBV) infection, no evidence of parasitic liver 
disease, no diabetes mellitus and no malignancy other 
than HCC. 
Ninety-four cases met the selection criteria. 
For each case: 
  A. Four-μm sections were cut from each 
paraffin block and stained with Hematoxylin and Eosin 
(H&E), Sirius red stain and Perl's Prussian blue 
stain.
 
 B. Detailed histopathological assessment was 
done regarding:  
1) the grade of inflammation and stage of 
fibrosis according to METAVIR scoring 
system [10]; 
2) the degree of steatosis according to the SAF 
algorithm [11]; and 
3) the presence of ferric iron as blue or purple 
deposits [12] in Perl's Prussian blue-stained 
sections. We expressed the results of an iron 
load as positive or negative.
 
 
  Immunohistochemical procedure 
Immunohistochemistry for NS3/NS4 was 
performed on sections cut from the paraffin blocks 
with a commercially available mouse monoclonal Anti-
Hepatitis C Virus NS3/NS4 antibody (ab113612, 
Abcam, USA). Briefly, 4 μm-thick sections are put 
onto positively charged slides (Superfrost plus, 
Menzel-Glaser, Germany) and the slides were stained 
by an automated platform—the Dako autostainer Link 
48. Heat-induced antigen retrieval was used for 30 
min at 97°C in the manufacturer’s high-PH EnVision™ 
FLEX Target Retrieval Solution and the primary 
antibody was used at a dilution of 1 in 50. Sections 
from wedge liver biopsy obtained during open 
cholecystectomy operation performed to a patient with 
no serological evidence of HCV infection were added 
in each run, and the antibody was omitted to serve as 
negative control. 
 
Interpretation of IHC 
Immunohistochemical assessment of 
hepatocyte viral content was performed according to 
Rullier et al. (2001) [13]. Cells with powder-like brown 
cytoplasmic granules were considered positive and 
were semi-quantitated: Score 0: 0% positive cells; +1: 
<10% positive cells; +2: 10%-50 % positive cells; +3: 
>50% positive cells. 
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Photomicrography
 
Photomicrographs included in this study were 
captured for significant results and data by AxioCam 
MRc5 camera mounted to Zeiss Scope A1 
Microscope (Hamburg, Germany).
 
 
FISH procedure 
VEGFR2 FISH probe labelled in Orange 5-
TAMRA dUTP was ordered from Empire Genomics 
(Buffalo, New York, USA) and preparation of slides 
was carried out according to their manual; Probe 
details: Gene: VEGFR2 (Orange 5-TAMRA dUTP), 
Loci: 4q12 and we use Spotlight FISH Tissue 
implementation kit (ZytoVision GmbH, Bremerhaven, 
Germany). 
Slides were deparaffinized in Xylene for 15 
min and repeated 1 more time. Then dehydrated in 
100%, 100%, 90%, +80% ethanol each for 5 min. 
Washed 2 times, each 2 min in deionized water, 
Pretreatment by incubating slides with heat 
pretreatment solution for 15 min at 98°C, transfer 
slides immediately to deionized water for 2 min two 
times. Apply pepsin solution and incubate for 15min at 
37°C. Then wash for 5 min in wash buffer SSC and 1 
min in deionized water then dehydrate in 70%, 90% 
and 100% ethanol, each for 1 min. Air dry slides. 
Denaturation and Hybridization by pipetting 15 µl of 
VEGF probe each onto individual samples. Denature 
the slides at 75°C for 10min (on the hot plate), transfer 
the slides to a humidity chamber and hybridise 
overnight at 37°C in a hybridization oven. Post-
hybridization and detection, remove the rubber 
cement by submerging in wash buffer for 3 min, and 
then incubate the slides in 70%, 90% and 
100%ethanol. Each for1 min. Air dry the samples 
while protected from light. Pipette 40 µl DAPI 
/DuraTect Solution on to the slides.
 
 
Interpretation of FISH 
We used fluorescence microscope (Olympus 
X51) [using 2 filters red (FITC) and DAPI] using a × 
100 oil immersion objective lens; the microscope is 
attached to high-resolution video camera (Jale) and 
monitor. We captured and interpreted photos using 
hardware (Cytovision 2.3, USA).
 
 
Statistical analysis 
SPSS software version 18 was used for data 
management and analysis. Quantitative data were 
presented as mean ± SD. Qualitative data were 
presented as frequencies and percentages. To study 
the relationship between variables, Spearman’s 
correlation coefficient was calculated. Tests were 
considered statistically significant when P< 0.05 
Results 
 
VEGF by immunohistochemistry in HCC 
and Cirrhotic groups
 
Cases of HCC (20 cases) were tested for 
expression of VEGF by immunohistochemistry, 
against cirrhotic cases (6 cases). 
Immunohistochemical expression of VEGF was found 
in 26%-50% of malignant hepatocytes (score 2) in 11 
cases of HCC, while 5 cirrhotic cases showed the 
immunohistochemical reaction in 51%-75% of 
hepatocytes (score 3). 
 
Table 1: Activity, iron load, steatosis and HCV-NS3/NS4 IHC 
expression in different studied groups 
 Group 1 Group 2 Group 3  Group 4  Total P 
 Number (%) Number (%) Number (%) Number (%) Number (%) value 
Activity         
A0  2 (4.4%) 0 (0%) 0 (0%)     0 (0%) 2 (2.1%) 
0.7 
A1  32 (71.1%) 7 (28%) 13 (72.2%) 2 (33.3%) 54 (57.4%) 
A2  11 (24.4%) 17 (68%) 5 (27.8%) 4 (66.7%) 37 (39.4%) 
A3 0 (0%) 1 (4%) 0 (0%)  0 (0%) 1 (1.1%) 
Total 45 (100%) 25 (100%) 18 (100%) 6 (100%) 94 (100%)  
Iron        
Positive 8 (17.8%) 3 (12%) 2 (11.1%)  0 (0%) 13 (13.8%) 
0.6 Negative  37 (82.2%) 22 (88%) 16 (88.9%) 6 (100%) 81 (86.2%) 
Total 45 (100%) 25 (100%) 18 (100%) 6 (100%) 94 (100%) 
 
Steatosis 
       
S0  28 (62.2%) 8 (32%) 10 (55.6%) 2 (33.3%) 48 (51.1%) 
0.2 
S1 9 (20%) 11 (44%) 6 (33.3%) 2 (33.3%) 28 (29.8%) 
S2 5 (11.1%) 2 (8%) 1 (5.6%) 2 (33.3%) 10 (10.6%) 
S3  3 (6.7%) 4 (16%) 1 (5.6%)  0 (0%) 8 (8.5%) 
Total 45 (100%) (100%) 18 (100%) 6 (100%) 94 (100%) 
        
HCV-NS3/NS4        
Negative (0)  13 (28.9%) 9 (36%) 8 (44.4%) 1 (16.7%) 31 (33%) 
0.6 
Score +1  15 (33.3%) 11 (44%) 8 (44.4%) 3 (50%) 37 (39.4%) 
Score +2  14 (31.1%) 4 (16%) 2 (11.1%) 2 (33.3%) 22 (23.4%) 
Score +3  3 (6.7%) 1 (4%) 0 (0%)  0 (0%) 4 (4.3%) 
Total 45 (100%) 25 (100%) 18 (100%) 6 (100%) 94 (100%) 
         
 
However, no expression in more than 75% 
(score 4) of hepatocytes was found in cirrhotic cases, 
in contrast to 6 cases (30%) of HCC with score 4 
expressions (Table 1-2, Figures 1-2).  
Table 2: VEGF IHC overexpression in different grades of HCC 
VEGF- IHC Score 
 HCC Grade   Total P value 
Grade I Grade II Grade III   
Number (%) Number (%) Number (%)    
VEGF (IHC)       
 0 (< 5%) 0 (0%) 0 (0%) 0 (0%)  0 (0%) 
<0.005 
 1(6% - 25%) 0 (0%) 0 (0%) 0 (0%)  0 (0%) 
 2(26% -50%) 8 (40%) 3 (15%) 0 (0%)  11 (55%) 
 3 (51% - 75%) 0 (0%) 2 (10%) 1 (5%)  3 (15%) 
 4 (> 75%) 0 (0%) 1 (5%) 5 (25%)  6 (30%) 
Total 8 (100%) 6 (100%) 6 (100%)  20 (100%) 
VEGFR2 (FISH)       
Normal 8 (40%) 4 (20%) 0 (0%)  12 (60%) 
<0.001 
Overexpression 0 (0%) 2 (10%) 6 (30%)  8 (40%) 
Total 8 (100%) 6 (100%) 6 (100%)  20 (100%)  
 
Our study showed that the immunoreactivity 
to VEGF in HCC is correlated with the degree of 
tumour differentiation. All poorly differentiated HCCs 
showed VEGF expression in more than 50% of 
hepatocytes while all well-differentiated tumours 
showed expression in less than 50% of hepatocytes.
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Figure 1: Liver sections: A and B showing marked steatosis and moderate portal inflammation respectively (HxE, 200x and 100x), C and D 
showing complete liver cirrhosis (Sirius red, 50x and 100x), E and F showing mild and moderate iron deposits (Prussian blue, 200x and 
100x), G, H and I showing Negative, score 1 and score 3 viral load (IHC, NS3/NS4, 50x, 100x and 1000x) 
 
VEGFR2 by FISH in different grades of HCC 
Overexpression of VEGFR2 correlated with 
the degree of differentiation in cases of HCC. Well-
differentiated HCCs showed normal expression of 
VEGFR2, while poorly differentiated tumours showed 
overexpression of the gene (Table 3; Figure 3). Our 
study has detected a strong correlation between the 
degree of immunoreactivity to VEGF and the 
amplification of VEGFR2 recorded by FISH technique. 
 
 
Figure 2: A) Case of CHC showing immunoreactivity to VEGF ±10%, IHC 100x. B) Liver biopsy from a cirrhotic case showing 
immunoreactivity to VEGF in about 60% of hepatocytes (Score 3); IHC 400x. C) Case of HCC showing immunoreactivity to VEGF in >75% 
of malignant hepatocytes (Score 4); IHC 400x 
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Discussion 
 
In the current study, a correlation between the 
stage of fibrosis and the grade of inflammation in 
cases of CHC was found (P < 0.01). These data are 
supported by the results of a study which included 
3068 patients with histologically confirmed CHC 
obtained from 10 clinical centres in Italy, Switzerland, 
France, Australia, and the United States. Leandro et 
al. [14] concluded that hepatic fibrosis, when 
considered as the dependent variable, was associated 
with a greater histologic activity, male sex, the 
presence of steatosis and older age. Also, in a study 
that included 346 CHC patients, Cua et al. [15] have 
linked hepatic fibrosis to the grade of portal/periportal 
inflammation and male gender. However, our study 
did not link male gender to higher grades of fibrosis (P 
= 0.3). 
Table 3: VEGFR2 FISH amplification in different cases of HCC 
    VEGFR2- FISH     
 VEGF- IHC Normal Amplified Total P value 
 Score Number (%) Number (%) Number (%)  
0 (< 5%) 0            (0%) 0 (0%) 0 (0%) 
< 0.001 
1 (6% - 25%) 0            (0%) 0 (0%) 0 (0%) 
2 (26% -50%) 11 (91.7%) 0 (0%) 11 (55%) 
3 (51% - 75%) 1 (8.3%) 2        (25%) 3 (15%) 
4 (> 75%) 0           (0%) 6        (75%) 6 (30%) 
 Total 12        (100%) 8       (100%) 20 (100%)  
 
Iron overload in our study was present in 
13.8% of CHC liver biopsies, and it was not correlated 
with the stage of fibrosis (P = 0.6) or the grade of 
inflammation (P = 0.9). These data are consistent with 
Lin et al. [16]; where they have identified iron in 12.5% 
of studied liver biopsies and they have concluded that 
both serum iron and hepatic iron correlate with serum 
indices of chronic liver disease but are not related to 
grade and stage of liver histology. However, Missiha 
et al. [17] have found that iron overload has been 
associated with accelerated fibrosis. A study 
conducted on 58 Egyptian CHC patients has found 
that hepatic iron density is an independent predictor of 
advanced fibrosis [18]. 
In the current study, the immunoreactivity 
against HCV-NS3/NS4 was found in 67% of CHC 
cases. However, this finding did not correlate with the 
stage of inflammation (P = 0.4) or the grade of fibrosis 
(P = 0.6) in cases of CHC. In accordance, Liao et al 
[19], after studying 214 retrospectively collected 
cases, stated that hepatocyte expression of HCV -
NS3 was not correlated with the serum viral load, a 
severity of the hepatic injury, or treatment response. 
On the other hand, in a study including 50 cases, 
Syed and Sadiq [5] have found a positive association 
between HCV-NS3 immunopositivity and the 
histological parameters of grading and staging. This 
discrepancy can be attributed to the variation in a 
number of studied cases as well as different HCV 
genotypes.
 
 
Figure 3: A) Case of HCC, G III, showing amplification of VEGFR2; 
more than two red signals in the nucleus; FISH X1000 B) from HCC 
grade II case showed high expression of VEGFR2 more than two 
red signals in the nucleus (FISH, magnification 1,000×) 
 
Steatosis in our study was present in 48.9% 
of cases with varying degrees. This percentage is 
slightly lower than that of another study (54%) 
including 92 CHC Egyptian patients [20]. It was also 
consistent with the percentage reported by Wyatt et 
al. [21] who studied 233 cases, 50.2% of which 
showed steatosis. 
Although steatosis was more prominent in 
groups with advanced fibrosis, no statistical 
correlation could be found between the steatosis and 
the stage of fibrosis in CHC patients (P = 0.2) in our 
study. This is consistent with a retrospective study 
performed on liver biopsies from 494 CHC patients by 
Perumalswami and colleagues [22]. They found that 
steatosis was associated with older age, higher BMI, 
and higher serum ALT levels but not with the 
presence of or subsequent progression of fibrosis. 
Our data are also consistent with Khokhar et al. [23]; 
in a study including 109 CHC patients, with no 
significant correlation could be found between 
steatosis and fibrosis. 
However, our data contradict what Leandro et 
al. [24] have found in large and geographically 
different group of CHC patients; whereas steatosis 
was confirmed as significantly and independently 
associated with fibrosis in CHC. Ahmed et al., [12] 
also have found that fibrosis was associated with high 
AST level, age ≥40 years, and steatosis. Gordon et al. 
[24] conducted a study including 74 CHC patients and 
reported that steatosis grade appears to relate to 
hepatic fibrosis progression rate in chronic hepatitis C 
genotype non-3. 
We have observed that the grade of 
inflammation increases with increasing steatosis. This 
observation, which couldn’t be proven statistically (P 
=0.2), is consistent with data from studying 221 liver 
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biopsy-proven CHC patients by Adinolfi et al. [3]; 
steatosis is an important cofactor in increasing liver 
necroinflammatory activity. Morosan et al. [25] have 
studied liver biopsies from 1206 patients (including 
1021 CHC patients) and have concluded that steatotic 
lesions associated with liver pathology increase the 
severity of the disease, regardless of the type of virus 
involved. Leandro et al. [14] have also found that 
steatosis was associated with higher BMI, older age 
and histologic activity. 
Most CHC cases with detectable iron, showed 
positive immunoreactivity to HCV-NS3/NS4 (11 out of 
13 cases), but no correlation could be found between 
the cellular viral load and the cellular iron content (P = 
0.1). Also, no significant correlation could be found 
between the cellular viral load and the degree of 
steatosis in CHC patients of this study (P = 0.7). 
Unfortunately, we did not record studies correlating 
the hepatic viral load (as detected by 
immunohistochemistry) with steatosis or hepatic iron 
content. 
We found that the expression of VEGF by IHC 
is more in HCC cases when compared to cirrhotic 
cases (P <0.001). This is compatible with a study 
including 90 Egyptian patients with CHC and HCC 
which has demonstrated that the highest value of 
VEGF expression by IHC was mostly encountered 
among HCC patients [26]. Another study that involved 
16 patients with HCC, has reported that VEGF protein 
expression was higher in HCC as compared to the 
surrounding liver tissue [27]. Iavarone and colleagues 
[28] have measured the serum levels of VEGF in 
patients with CHC (with or without cirrhosis) and HCC. 
They have reported that serum levels of VEGF protein 
were significantly higher in HCC patients than in 
cirrhotic patients. Our study has also found a strong 
correlation between the expression of VEGF and the 
degree of HCC differentiation (P <0.001). This is 
consistent with Mi et al. [29]. They have found a 
positive relationship between the expression of VEGF 
in HCC tissue and the pathological differentiation and 
invasion of the tumour. Another study performed on 
54 Egyptian HCC patients has found a statistically 
significant correlation between expression of VEGF 
and histopathological grading of HCC [30]. 
We conclude that the grade of inflammation is 
a factor affecting the stage of fibrosis in CHC. The 
degree of liver damage is not related to cellular viral 
load, iron load or copper load. Steatosis is associated 
with higher grades of inflammation and stages of 
fibrosis. VEGF by immunohistochemistry is correlated 
with the overexpression of VEGFR2 by FISH 
technique. 
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